Each year over 6M patients require a central venous catheter (CVC) for a wide variety of therapies – it is one of the top procedures performed in the hospital. Up to 52% of patients who receive a CVC will experience some degree of thrombosis, with a significant portion of these patients going on to develop a symptomatic venous occlusion. Based on the above, there are ~133,333 patients/each year with symptomatic occlusions in the US and Europe, making this a 3.4 Billion addressable market.

BVT has an outstanding team of seasoned industry professionals, with significant experience and success taking medical device start-ups from inception to third party sale. CEO Gabriele Niederauer has been with BVT for over six years and has spent >30 years in product development and commercialization of 3 separate medical device companies with all three of companies being acquired (ENTrigue Surgical –>ArthroCare, C2M Medical –> Tornier, OsteoBiologics –> Smith & Nephew) with positive returns.
BVT has engaged a world-wide distributor, Merit Medical. In Europe, Merit Medical has ~25 Sales Representatives that cover the main continent of Europe with additional resources/distributors covering remote regions. In the US, Merit Medical currently has ~30 Sales Representatives that cover the United States., with a Surfacer Marketing, Sales and Training team managing the limited US launch. Nine peer-reviewed publications support the safe and effective performance of the Surfacer System.
No other FDA approved and CE marked devices are available for chronically occluded central venous access. Other approaches, such as “Sharp Recanalization” using off-label components and only done by select surgeons, have a low success rate (0-67% ), take long surgical time (up to 3 hours ), require extremely skilled interventional radiologists and costs over $2,000 more than use of the Surfacer System.